Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic Cancer Dietary Assessment-PanDA)
Name:
37190204.pdf
Size:
1.191Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Carnie, Lindsay EShah, Dinakshi
Vaughan, Kate
Kapacee, Zainul Abedin
McCallum, L.
Abraham, Marc
Backen, Alison C
McNamara, Mairead G
Hubner, Richard A
Barriuso, Jorge
Gillespie, Loraine
Lamarca, Angela
Valle, Juan W
Affiliation
Nutrition & Dietetics, The Christie NHS Foundation Trust, Manchester M20 4BX, UKIssue Date
2023
Metadata
Show full item recordAbstract
Introduction: Pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC) is well documented, but there is no consensus regarding optimal screening. Methods and analysis: Patients diagnosed with aPC referred for palliative therapy were prospectively recruited. A full dietetic assessment (including Mid-Upper Arm Circumference (MUAC), handgrip and stair-climb test), nutritional blood panel, faecal elastase (FE-1) and 13C-mixed triglyceride breath tests were performed. Primary objective: prevalence of dietitian-assessed PEI (demographic cohort (De-ch)); design (diagnostic cohort (Di-ch)) and validation (follow-up cohort (Fol-ch)) of a PEI screening tool. Logistic and Cox regressions were used for statistical analysis. Results: Between 1 July 2018 and 30 October 2020, 112 patients were recruited (50 (De-ch), 25 (Di-ch) and 37 (Fol-ch)). Prevalence of PEI (De-ch) was 64.0% (flatus (84.0%), weight loss (84.0%), abdominal discomfort (50.0%) and steatorrhea (48.0%)). The derived PEI screening panel (Di-ch) included FE-1 (normal/missing (0 points); low (1 point)) and MUAC (normal/missing (>percentile 25) (0 points); low (2 points)) and identified patients at high-risk (2-3 total points) of PEI [vs. low-medium risk (0-1 total points)]. When patients from the De-ch and Di-ch were analysed together, those classified by the screening panel as "high-risk" had shorter overall survival (multivariable Hazard Ratio (mHR) 1.86 (95% CI 1.03-3.36); p-value 0.040). The screening panel was tested in the Fol-ch; 78.4% patients classified as "high-risk", of whom 89.6% had dietitian-confirmed PEI. The panel was feasible for use in clinical practice (64.8% patients completed all assessments), with high acceptability (87.5% would repeat it). Most patients (91.3%) recommended dietetic input for all patients with aPC. Conclusions: PEI is present in most patients with aPC; early dietetic input provides a holistic nutritional overview, including, but not limited to, PEI. This proposed screening panel may help to prioritise those at higher risk of PEI, requiring urgent dietitian input. Its prognostic role needs further validation.Citation
Carnie LE, Shah D, Vaughan K, Kapacee ZA, McCallum L, Abraham M, et al. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment-PanDA). Cancers (Basel). 2023 Apr 13;15(8). PubMed PMID: 37190204. Pubmed Central PMCID: PMC10136984. Epub 2023/05/16. eng.Journal
CancersDOI
10.3390/cancers15082277PubMed ID
37190204Additional Links
https://dx.doi.org/10.3390/cancers15082277Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/cancers15082277
Scopus Count
Collections
Related articles
- Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol.
- Authors: Carnie LE, Lamarca A, Vaughan K, Kapacee ZA, McCallum L, Backen A, Barriuso J, McNamara MG, Hubner RA, Abraham M, Valle JW
- Issue date: 2021 May 13
- Pancreatic exocrine insufficiency in diabetes mellitus - prevalence and characteristics.
- Authors: Søfteland E, Poulsen JL, Starup-Linde J, Christensen TT, Olesen SS, Singh S, Vestergaard P, Drewes AM, Dimcevski G
- Issue date: 2019 Oct
- Screening for undiagnosed pancreatic exocrine insufficiency (PEI) in a cohort of diabetic patients using faecal elastase testing and PEI scoring system.
- Authors: Parihar V, Ballester R, Ridgway PF, Conlon KC, Gibney J, Ryan BM
- Issue date: 2024 Oct
- Abbreviated (13)C-mixed triglyceride breath test for detection of pancreatic exocrine insufficiency performs equally as standard 5-hour test in patients after gastrectomy performed for gastric cancer.
- Authors: Siuka D, Kumer K, Stabuc B, Stubljar D, Drobne D, Jansa R
- Issue date: 2022 Aug 14
- Diagnosis and management of pancreatic exocrine insufficiency.
- Authors: Nikfarjam M, Wilson JS, Smith RC, Australasian Pancreatic Club Pancreatic Enzyme Replacement Therapy Guidelines Working Group
- Issue date: 2017 Aug 21